Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
Single center, single-dose, randomized, placebo-controlled, dose-escalating study to evaluate, safety, tolerability, pharmacokinetics, and pharmacodynamics of escalating doses of ENT-03S in obese but otherwise healthy subjects and in subjects with obesity and Type 2 diabetes.
Epistemonikos ID: b969142c8dc1ff18fa8d458d5a6b1c24b5c49343
First added on: May 15, 2024